Impact of second primary esophageal or lung cancer on survival of patients with head and neck cancer
Received 12 November 2009; received in revised form 28 December 2009; accepted 4 January 2010. published online 08 February 2010.
Summary
Second cancers following head and neck cancer (HNC) most often involve the esophagus and lung, yet the actual magnitude of impact of second primary esophageal or lung cancer on survival of HNC patients has not been well established, particularly by a large-scale epidemiological study. To provide a quantitative estimate of the survival impact, we conducted a population-based study including 63,720 cases of HNC subsets, of which 3658 developed at least one second primary malignancy, 253 had a second esophageal cancer and 388 had a second lung cancer. A Cox proportional hazards model which included age at initial cancer diagnosis and gender were employed to compare the survival rates between patients with different types of second cancers. Our results showed that the second esophageal or lung cancer contributed to a poorer outcome than the other types of second cancer, regardless of the index tumor site (all Ps⩽0.019). The overall median survival was 0.76±0.04 and 0.72±0.08years for second esophageal and lung cancers, respectively. Compared to those without second cancers, the patients with second esophageal or lung cancer were associated with a significant reduction in survival, with an estimated 31–105% excess risk of death according to the site of the primary index tumor. In conclusion, the second esophageal and lung cancers have a significantly negative impact on the survival of HNC patients, thereby calling for a more effective program for surveillance and chemoprevention for these two sites.
aDepartment of Public Health and Biostatistics Consulting Center, School of Medicine, Chang Gung University, Tao-Yuan, Taiwan
bDepartment of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan
cDepartment of Medicine, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Tao-Yuan, Taiwan
dDepartment of Hematology and Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan
eChang Gung Institute of Technology, Chiayi, Taiwan
Corresponding author. Address: Department of Hematology and Oncology, Chang Gung Memorial Hospital, 6 West Sec., Chia-Pu Road, Pu-Tz city, Chiayi 613, Taiwan. Tel.: +886 5 3621000x2772; fax: +886 5 3623781.